Datafarm Announces the Release of Web-Based eCTD Viewer
Datafarm announces the release of a simple and cost effective Web-based eCTD viewer for companies of all sizes.
Philadelphia, 19 June 2006-Datafarm, the leading provider of electronic regulatory submission solutions, today announced the availability of eCTDViewer® Web Edition Version 3.0. This Web-based eCTD viewing solution includes support for all recent eCTD specifications and guidelines published by ICH, FDA, EMEA (including the most recent v1.2 specifications), Japan, Health Canada and Taiwanese agencies. This business tool offers zero desktop footprint and is designed meet the needs of companies of all sizes.
eCTDViewer Web Edition is built upon recognized technology standards such as HTML, XML, and JAVA. This combination of cross-platform technologies makes the application easy to deploy on both Windows and Linux servers, and allows it to support multiple application servers such as BEA WebLogic and Apache Tomcat. By using this standards-based approach, Datafarm has made it possible for any organization, regardless of size, to seamlessly incorporate eCTDViewer® Web Edition into their existing environment.
Datafarm's eCTD suite of applications includes eCTDBuilder®, used for submission compilation, and eCTDViewer® for submission review and paper dossier creation. This suite is currently used by over 40 companies in the US, EU, Canada and Japan who have successfully submitted over 800 submissions to the regulatory authorities.
Merck Stops HYPERION Trial for Winrevair in PAH Following Positive ZENITH Trial Results
January 30th 2025The Phase III HYPERION trial was stopped early after strong positive interim results from the ZENITH trial demonstrated the efficacy of Winrevair (sotatercept-csrk) in treating pulmonary arterial hypertension, making it unethical to continue.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
